The incidence of drug-resistant pathogens differs greatly between countries according to differences in the usage of antibiotics. The purpose of this study was to investigate the phenotypic resistance of 321 methicillin resistance Staphylococcus aureus (MRSA) and 195 methicillin susceptible S. aureus (MSSA) in a total of 516 S. aureus strains to macrolide, lincosamide, streptogramin B (MLS B ), ketolid, and linezolid. Disk diffusion method was applied to determine MLS B phenotype and susceptibility to different antibiotic agents. It was found that 54.6% of the isolates were resistant to erythromycin (ERSA), 48% to clindamycin, 55% to azithromycin, 58.7% to spiramycin, 34.7% to telithromycin, and 0.4% to quinupristin-dalfopristin, respectively. No strain resistant to linezolid was found. The prevalence of constitutive (cMLS B ), inducible (IMLS B ), and macrolides and type B streptogramins (M/MS B ) among ERSA isolates (237 MRSA, 45 MSSA) was 69.6 %, 18.2%, and 12.2 % in MRSA and 28.9%, 40%, and 31.1% in MSSA, respectively. In conclusions, the prevalence of cMLS B was predominant in MRSA; while in MSSA strains, iMLS B and M/MS B phenotype were more higher than cMLS B phenotype resistance. The resistance to quinupristindalfopristin was very low, and linezolid was considered as the most effective antibiotic against all S.aureus strains.
INTRODUCTION
Macrolides (e.g., erythromycin, azithromycin, spiramycin), lincosamides (e.g., clindamycin, lincomycin), and streptogramin B (e.g., quinupristin) are groups of antibiotic collectively named MLS B .
1 They are chemically distinct, but have similar inhibitory effects on bacterial protein synthesis. MLS B , commonly used in treatment of staphylococcal infections, 1 and clindamycin is a frequent choice for some staphylococcal infections, particularly skin and soft-tissue infections, and it is an alternative in the penicillin-allergic patients. 2 The macrolide antibiotic resistance in S. aureus is usually caused either by ribosomal modification mediated by 23S rRNA methylases encoded by erm genes, or by active efflux of the antimicrobial agent by an ATP-dependent pump encoded by msrA gene. Methylases confer inducible (iMLS B ) or constitutive (cMLS B ) resistance, while the efflux mechanism affects only macrolides and type B streptogramins (M/MS B ). Other more rare macrolide resistance mechanisms include ribosomal mutations and antibiotic inactivation by specific hydrolases or phosphotransferases. 3 Ketolides belong to the MLS B family, and telithromycin is the first commercially available ketolide. 4 Oxazolidinones and specifically linezolid are new class of compounds that binds to the 23S portion of the 50S ribosomal subunit, preventing initiation complex formation with activity against methicillin-resistant S. aureus (MRSA) and vancomycin-resistant Enterococcus spp. (VRE). 5 Quinupristin-dalfopristin (Synercid, 30:70 ratio) is the first parenteral streptogramin that has recently been licensed for clinical use in the United States and Europe for the treatment of infections caused by multidrug resistant and Gram-positive pathogens. 6 Quinupristin and dalfopristin enter bacterial cells by diffusion and bind to different sites on the 50S ribosomal subunit, resulting in an irreversible inhibition of bacterial protein synthesis. The combination synergistic effect appears to result from the fact that these compounds target early and late steps in protein synthesis.
In vitro tests show that strains with constitutive resistance are resistant to all macrolides, which comprise 14-(e.g.erythromycin), 15-(e.g.azithromycin), and 16-membered rings (e.g. spiramycin), lincosamides, and streptogramin B, while inducibly-resistant strains are resistant only to 14-and 15-membered-ring macrolides. 3 The objective of the present study was to investigate prevalence of MLS B , ketolid, and linezolid phenotypic resistance in clinical S. aureus strains. 
MATERIAL AND METHODS

Bacterial strains
Antimicrobial disks
Antimicrobial disks were purchased from Oxoid (Hemakim, Istanbul, Turkey).
Determination of antimicrobial susceptibility test and MLS B phenotype resistance patterns
MLS B phenotype resistance pattern was determined according to the method advised by Clinical and Laboratory Standards Institute (CLSI). 8 Briefly, an overnight culture of each isolate was adjusted to 0.5 McFarland (10 8 cf/mL) and spread on unsupplemented Mueller-Hinton agar (HIME-DIA, Himedia Laboratories, Mumbai , India). The following antibiotic disks were applied on an inoculated media: azithromycin (Az-15 μg), spiramycin (Sp 100 μg), telithromycin (Te-15 μg), quinupristin-dalfopristin (Q-D-15 μg), and linezolid (Li-30 μg), erythromycin (E-15 μg), and clindamycin (Cl-2 μg) disks were placed by hand to provide distances of 15-26 mm from edge to edge. Following incubation for 16 to 18 hours at 35° C, zone diameters were measured in the usual manner; any flattening or blunting of clindamycin zone shape (D-shape), indicating iMLS B , while resistance to both erythromycin and clindamycin indicated cMLS B . Lack of a D-shaped zone in erythromycin resistant and clindamycin-susceptible isolates were interpreted as M/MS B . Due to lack of CLSI zone diameters criteria for spiramycin, we used the Comite´ de l'Antibiogramme de la Socie´te´ Française de Microbiologie recommendation of zone diameters ≥  24 mm as susceptible, and < 19 mm as resistance.
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RESULTS
Of the 516 isolates, 237 MRSA and 45 MSSA, a total of 282 (54.6%) S. aureus isolates were found to be resistant to erythromycin (ERSA) and the rest was susceptible to erythromycin (ESSA), 248 (48%) isolates were resistant to clindamycin, 284 (55%) to azithromycin, 303 (58.7%) to spiramycin, 179 (34.7%) to telithromycin, and two (0.4%) strains to quinupristin-dalfopristin. No strain resistant to linezolid was found. As for phenotypic resistance of ERSA isolates, the rate of cMLS B , iMLS B , and M/MS in 282 ERSA strains was 178 (63%) cMLS B , 61 (22%) iMLS B , and 43 (15%) M/MS B , respectivley. The distribution of cMLS B , iMLS B , and M/MS B in ERSA-MRSA isolates was 69.6 %, 18.2%, and 12.2 %; and in ERSA-MSSA isolates it was 28.9%, 40%, and 31.1%, respectively, which showed a predominance of cMLS B in MRSA, while iMLS B and M/MS B phenotypic resistance patterns were higher in MSSA isolates (Table 1) .
DISCUSSION
This study was conducted at the largest educational hospital in Istanbul-Turkey to investigate the prevalence of MLS B , ketolid, and linezolid in 516 S. aureus isolates. The prevalence of ERSA in Turkish isolates was found to be higher (54.6%) than those obtained (39%) in a study perfomed by the neighbours of Turkey with the participation of 20 European university hospitals. 10 This differance is more likely attributed to the high proportion of MRSA (62.2%) in our S .aureus isolates compaed to that of the European study (22%). However, they also reported 10 higher rate of cMLS B in MRSA (93%) and MSSA (44%) than we obtained in MRSA (69.6%) or in MSSA isolates (28.9%). Aktas et al. 11 conducted a study at the University hospital in Turkey on only 22 MRSA and found that 63%, 18%, and 18% of the isolates exhibited cMLS B , iMLS B , and M/MS B , respectively. Spiliopoulou et al. 12 have mentioned in a study on ERSA strains that only 5.3% of MRSA isolates expressed iMLS B and the rest displayed cMLS B , while in MSSA, 78.3% were iMLS B and 21.7% were M/MS B , similar with our finding in which the percentage of M/MS B (31.1%) in MSSA was twofold higher (12.2%) than in MRSA. A study of Janapatla et al. 13 from Taiwan reported that iMLS B was predominant in MSSA (8%) than in MRSA (4%). Otsuka et al. 14 have also reported that 61.3% of the Japanese MRSA isolates expressed cMLS B and 94% of the MSSA isolates displayed iMLS B . A retrospective study conducted by Modak et al. 15 on 13,946 S. aureus strains collected between 1994-2005 revealed a stable incidence of cMLS B strains, but also a significant increase in the incidence of isolates that were susceptible to clindamycin and resistant to erythromycin, and in iMLS B . They attributed this high incidence to the increased use of macrolides and clindamycin during the same period. Merino-Díaz et al. 16 reported that the rate of iMLS B resistance was significantly higher in S. aureus (5.2%) than the rate of cMLS B (1.7%) in cutaneous strains from Spain. On the other hand, 41.5% of the ESSA isolates (44.7% of MSSA and 35.7% of MRSA) were highly resistant to spiramycin, in contrast to the low resistance rate to clindamycin (4%) and azithromycin (1%). The ribosomal mutations and antibiotic inac- tivation are the mechanisms that might play a role in the last resistance of ESSA and differ from MLS B . 3 Only 0.4% of the S. aureus isolates were resistant to quinupristin-dalfopristin and this agent was effective in all of the examined isolates. There was concern regarding the use of streptogramin antibiotic (virginiamycin) as a feed additive in the animal husbandry and development of cross-resistance against this antibiotic.
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Although the first resistance to linezolid was reported in 2001 due to mutations in the 23S rRNA, 18 we did not detect any resistance or even decreased susceptibility to this antibiotic, and most reports have shown that the resistance rate to this agent is still low. [18] [19] [20] Our study and review of the studies related to macrolides resistance in S. aureus demonstrated that methicillin resistance leads physicians to use different macrolides, mainly eryhromycin, azithromycin, and spiramycin or lincosamides, such as clindamycin and lincomycin which facilitate development of different MLS B phenotypic patterns, and which mostly end with resistance to macrolides, lincosamide, streptogramin B, and ketolid (cMLS B ). We believe that this is the reason behind the increased prevalence of cMLS B in geographical area with high prevalence of MRSA, and vice versa.
Our study showed that the prevalence of MLS B in Turkish S. aureus isolates was high and that the predominant phenotype was cMLS B in MRSA and iMLS B and M/MS B in MSSA isolates, which is in agreement with reports of most countries. Linezolid and quinupristin-dalfopristin were very effective and promising. The accurate use of these new agents might avoid treatment failure especially in macrolid-resistant S. aureus infections.
